Status:
COMPLETED
A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
Lead Sponsor:
Bracco Diagnostics, Inc
Conditions:
CIN
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficienc...
Eligibility Criteria
Inclusion
- Referred for cardiac angiography; with a documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2
Exclusion
- Unstable renal function; concurrent administration of nephrotoxic drugs, undergoing dialysis
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00289029
Start Date
July 1 2005
End Date
June 1 2006
Last Update
August 18 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bracco Diagnostics, Inc
Princeton, New Jersey, United States